FLAB 2018

Palestrantes Internacionais Confirmados

CO-DIRECTOR OMI REUMATÓLOGO EN ORGANIZACIÓN MÉDICA DE INVESTIGACIÓN (OMI) - URUGUAY 725 PB, CAPITAL FEDERAL, BUENOS AIRES, ARGENTINA INVESTIGADOR PRINCIPAL EN PROTOCOLOS PARA EMPRESAS FARMACÉUTICAS NACIONALES E INTERNACIONALES. SUB-INVESTIGADOR EN PROTOCOLOS DE FASE II, III Y IV PARA EMPRESAS FARMACÉUTICAS NACIONALES E INTERNACIONALES INCLUYEN PROTOCOLOS DE ARTRITIS REUMATOIDE, ARTRITIS PSORIÁSICA, DOLOR LUMBAR, OSTEOPOROSIS
DR. FREDDY FACCIN L, IS THE GLOBAL TA LEAD, GLOBAL MEDICAL AFFAIRS, BIOTHERAPEUTICS (ABBVIE). IN 1988, HE RECEIVED HIS MEDICAL DEGREE FROM THE UNIVERSIDAD CENTRAL DE VENEZUELA (CARACAS, VENEZUELA) WITH SUMMA CUM LAUDE MENTION. HE ALSO RECEIVED HIS POST-GRADUATE DEGREE AS OPHTHALMOLOGIST GRANTED BY THE UNIVERSIDAD CENTRAL DE VENEZUELA IN 1994. UNTIL THE END OF 1998, HE PRACTICED CLINICAL OPHTHALMOLOGY IN VENEZUELA. HE JOINED ELI LILLY IN 1998, WORKING IN DIFFERENT MEDICAL ROLES. HE JOINED ABBOTT VENEZUELA IN 2001 AS MEDICAL MANAGER, AND THEN AS MEDICAL DIRECTOR FOR VENEZUELA, CENTRAL AMERICA AND THE CARIBBEAN REGION. IN 2008 HE WORKED AS MEDICAL MANAGER FOR SPECIALTY PRODUCTS IN THE LATIN AMERICA REGION WHERE HE WAS PART OF ABBOTT'S BIOTHERAPEUTICS TEAM WHICH HE LED FROM 2008 - 2011 BEING PROMOTED TO ASSOCIATE MEDICAL DIRECTOR - BIOTHERAPEUTICS AND IN 2014 TO HIS CURRENT ROLE AS TA LEAD, BIOTHERAPEUTICS, GLOBAL MEDICAL AFFAIRS, GPRD.
HAS PARTICIPATED AS SPEAKER AT SEVERAL SCIENTIFIC AND BIOSIMILARS FORUMS IN ASIA AND LATIN AMERICA, INCLUDING THE I, II AND IV, V, VI AND VII BRAZILIAN AND LATIN AMERICAN BIOSIMILARS FORUM (2010, 2011, 2013, 2014, 2015 AND 2016), THE I BIOSIMILARS LATAM MEETING (2015), THE 2011 APEC BIOSIMILARS FORUM (SEOUL, KOREA), THE 2011 RUSSIAN HEALTH TECHNOLOGY ASSESSMENT FORUM (RIGA, LATVIA), THE 2013 SPRING CONFERENCE OF THE KOREAN SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (HSCPT), THE 2013 CHILEAN CONGRESS OF RHEUMATOLOGY, THE 2013 APEC HARMONIZATION CENTER BIOTHERAPEUTICS WORKSHOP, THE 2014 PANLAR MEETING (PUNTA DEL ESTE, URUGUAY), THE 5TH FIP PHARMACEUTICAL SCIENCES WORLD CONGRESS (MELBOURNE, AUSTRALIA, APRIL 2014), THE 2014 BIO INTERNATIONAL CONVENTION (SAN DIEGO, CALIFORNIA, USA) AND THE BIO LATAM CONVENTION (RIO DE JANEIRO, BRAZIL), THE 2014 PRE-ICDRA ANNUAL MEETING (RIO DE JANEIRO, BRAZIL), THE 2014 AND 2016 ARGENTINA RHEUMATOLOGY SOCIETY ANNUAL MEETING (SALTA; MENDOZA, ARGENTINA), THE 2015 ANNUAL MEETING OF THE VENEZUELA SOCIETY OF ALLERGY AND IMMUNOLOGY (VALENCIA, VENEZUELA), THE 2015 "BIOTECHNOLOGY: A LOOK INTO THE FUTURE" WORKSHOP (CARACAS, VENEZUELA), THE 2015 COLOMBIAN CONGRESS OF RHEUMATOLOGY (CALI, COLOMBIA), THE 2015 INTERNATIONAL FORUM ON BIOTECHNOLOGY (MEXICO CITY, MEXICO), THE 2015 ANNUAL COSTA RICA GASTROENTEROLOGY CONGRESS, THE 2016 INTERNATIONAL CONFERENCE ON PHARMACEUTICAL MEDICINE (SAO PAULO, BRAZIL), AMONG OTHERS.
ALSO HAS SERVED AS EXTERNAL SPEAKER AND CONSULTANT TO REGULATORY AGENCIES AND OTHER RELEVANT AUDIENCES SUCH AS KFDA (SOUTH KOREAN FDA),TFDA (TAIWAN FDA), DRUG ADVISORY COMMITTEE (HONG KONG), THE MEDICAL DEVELOPMENT DEPARTMENT (MALAYSIA), THE SFDA (SAUDI ARABIA'S FDA), JFDA (JORDAN'S FDA), THE UNITED ARAB EMIRATES' AND OMAN'S MINISTRIES OF HEALTH, SOUTH AFRICA'S MEDSCHEME AND METROPOLITAN HEALTH, SINGAPORE'S HEALTH SCIENCES AUTHORITY, THE DOMINICAN REPUBLIC DGDF, EL SALVADOR DNM, GUATEMALA MSP, PANAMA DNFD, AMONG OTHERS.
DR CASTAÑEDA-HERNÁNDEZ IS CURRENTLY THE SENIOR INVESTIGATOR AT THE DEPARTMENTO DE FARMACOLOGÍA (DEPARTMENT OF PHARMACOLOGY), CENTRO DE INVESTIGACIÓN Y ESTUDIOS AVANZADOS DEL INSTITUTO POLITÉCNICO NACIONAL (CENTRE FOR RESEARCH AND ADVANCED STUDIES OF THE NATIONAL POLYTECHNIC INSTITUTE), MÉXICO CITY, MEXICO.
HIS PAST PUBLICATIONS INCLUDE 185 RESEARCH AND REVIEW ARTICLES IN SCIENTIFIC JOURNALS AND A TEXTBOOK ON BIOAVAILABILITY AND BIOEQUIVALENCE.
DR CASTAÑEDA-HERNÁNDEZ'S QUALIFICATIONS INCLUDE A PHD IN PHARMACOLOGY FROM FACULTÉ DE MÉDECINE, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, BELGIUM, AND A BSC IN BIOLOGY FROM DIVISIÓN DE CIENCIAS BIOLÓGICAS Y DE LA SALUD, UNIVERSIDAD AUTÓNOMA METROPOLITANA, MEXICO CITY, MEXICO.
HEAD REGULATORY AFFAIRS POLICY AT SANDOZ.
BETWEEN 2001 AND 2017 INGRID WAS HEAD GLOBAL REGULATORY AFFAIRS FOR SANDOZ BIOPHARMACEUTICALS. UNDER HER RESPONSIBILITY AS HEAD THE GLOBAL REGULATORY AFFAIRS TEAM, WHICH IS DEDICATED TO BIOSIMILAR APPLICATIONS WORLDWIDE, NUMEROUS PIONEERING MILESTONES IN THE HISTORY OF BIOSIMILARS WERE ACHIEVED:
- APPROVALS OF OMNITROPE® (SOMATROPIN) - THE FIRST BIOSIMILAR PRODUCT APPROVED EVER - IN EUROPE, AUSTRALIA, USA, JAPAN, AND CANADA AS WELL AS IN MANY OTHER COUNTRIES GLOBALLY
- SUCCESSFUL REGISTRATIONS OF BINOCRIT® (EPOETIN ALFA), THE FIRST COMPLEX BIOSIMILAR PRODUCT APPROVED EVER, AND OF ZARZIO® (FILGRASTIM) IN THE EU
- APPROVAL FOR THE FIRST BIOSIMILAR PRODUCT EVER IN THE US: ZARXIO® (FILGRASTIM)
- APPROVAL OF THE SANDOZ FIRST MORE COMPLEX BIOSIMILAR IN THE US, ERELZI® (ETANERCEPT)
- APPROVALS OF TWO MORE BIOSIMILAR IN THE EU: ERELZI® (ETANERCEPT) AND RIXATHON® (RITUXMAB)
- SUCCESSFUL MAINTENANCE OF MORE THAN 200 APPROVALS IN OVER 90 COUNTRIES IN THE WORLD
FARMACOLOGISTA, PROFESSOR E INVESTIGADOR DA FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA.
DOCTOR EN BIOQUÍMICA (UNIVERSIDAD NACIONAL DE ROSARIO, ARGENTINA), POSTDOCTORADO EN ONCOLOGÍA MOLECULAR (BARCELONA, ESPAÑA). INVESTIGADOR DEL CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET). DOCENTE DE GENÉTICA Y ONCOLOGÍA DE LA FACULTAD DE CIENCIAS MÉDICAS Y PROFESOR INVITADO EN LA CARRERA DEL DOCTORADO EN CIENCIAS BIOMÉDICAS, UNIVERSIDAD NACIONAL DE ROSARIO. DIRECCIÓN DE PROYECTOS DE INVESTIGACIÓN EN ONCOLOGÍA E INMUNOLOGÍA, EN TEMAS DE INMUNOTERAPIA DEL CÁNCER, TERAPIAS DIRIGIDAS A BLANCOS MOLECULARES E IDENTIFICACIÓN DE BIOMARCADORES. INMUNOTERAPIAS COMBINADAS. INVESTIGACIÓN TRASLACIONAL. PUBLICACIONES EN REVISTAS INTERNACIONALES CON REFERATO, LIBROS Y PRESENTACIONES EN CONGRESOS INTERNACIONALES. EXPERTO Y ASESOR EXTERNO DE LA INDUSTRIA FARMACÉUTICA EN BIOTECNOLOGÍA Y MEDICAMENTOS BIOTECNOLÓGICOS. ORGANIZACIÓN Y EXPOSICIÓN EN PROGRAMAS DE FORMACIÓN PROFESIONAL MÉDICA CONTINUA DIRIGIDA A MÉDICOS ESPECIALISTAS EN ONCOLOGÍA, REUMATOLOGIA, HEMATOLOGÍA Y NEUROLOGÍA. PLANIFICACIÓN, ORGANIZACIÓN Y EXPOSICIÓN EN JORNADAS, CURSOS, SIMPOSIOS Y FOROS CIENTÍFICOS EN TEMAS DE BIOTECNOLOGÍA, MEDICAMENTOS BIOTECNOLÓGICOS Y MEDICINA PERSONALIZADA. ASESORAMIENTO DE AGENCIAS REGULATORIAS DE LATINOAMÉRICA SOBRE MEDICAMENTOS BIOTECNOLÓGICOS. EX-BECARIO DE LA AMERICAN ASSOCIATION FOR CANCER RESEARCH, FUNDACIÓN CAROLINA Y AGENCIA ESPAÑOLA DE COOPERACIÓN INTERNACIONAL, Y LIGA ARGENTINA DE LUCHA CONTRA EL CÁNCER (LALCEC).
ROBERT MOOTS IS PROFESSOR OF RHEUMATOLOGY AT THE UNIVERSITY OF LIVERPOOL, DIRECTOR OF THE UNIVERSITY OF LIVERPOOL ACADEMIC RHEUMATOLOGY UNIT AND CONSULTANT RHEUMATOLOGIST AT AINTREE UNIVERSITY HOSPITAL. AFTER QUALIFYING IN MEDICINE IN LONDON, UK, DR MOOTS SUBSEQUENTLY TRAINED IN IMMUNOLOGY AT THE INSTITUTE FOR MOLECULAR MEDICINE AT THE UNIVERSITY OF OXFORD, WHERE HE EARNED HIS PHD. DR MOOTS CONTINUED HIS RESEARCH AT HARVARD MEDICAL SCHOOL. HE RETURNED TO THE UK IN 1997 AND IN 2002 BECAME THE YOUNGEST FULL PROFESSOR OF RHEUMATOLOGY AND HEAD OF DEPARTMENT APPOINTED IN THE UK.
DR MOOTS' RESEARCH INTERESTS LIE IN CLINICAL AND BASIC SCIENCE ASPECTS OF RHEUMATIC DISEASES, FROM BENCH TO BEDSIDE. HE HAS PUBLISHED EXTENSIVELY, WON THE PRESTIGIOUS MICHAEL MASON PRIZE FOR RHEUMATOLOGY RESEARCH, IS ACTIVE IN INTERNATIONAL MEDICAL AND SCIENTIFIC SOCIETIES AND COMMITTEES AND EACH YEAR RECEIVES INVITATIONS TO LECTURE ON EVERY CONTINENT. DR MOOTS HAS EXTENSIVE EXPERIENCE IN DRUG DEVELOPMENT - WORKING WITH THE PHARMACEUTICAL INDUSTRY INTERNATIONALLY AND WITH BODIES SUCH AS THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE). HE IS MEDICAL ADVISOR TO MAJOR UK PATIENT GROUPS AND IN 2009 TOOK OVER AS EDITOR-IN-CHIEF OF RHEUMATOLOGY. CLINICAL SERVICE REMAINS AN IMPORTANT PART OF HIS WORK AND HIS UNIT HAS RECENTLY BEEN DESIGNATED UK NATIONAL CENTRE FOR BEHÇET'S DISEASE.